Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
1. Senti Bio will hold a live investor webcast on April 23rd. 2. CEO and CMO will discuss the company's pipeline and strategies. 3. Senti Bio develops cell and gene therapies using Gene Circuit technology. 4. SENTI-202 is currently in Phase I clinical trials. 5. Preclinical success demonstrated in targeting solid tumors and blood cancers.